Omidenepag
Clinical data | |
---|---|
Trade names | Eybelis, Omlonti |
Other names | UR-7276, DE-117, Omidenepag isopropyl (JAN JP) |
Routes of administration | Topical eye drops |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H28N6O4S |
Molar mass | 520.61 g·mol−1 |
3D model (JSmol) | |
| |
|
Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.[1][3]
Omidenepag was approved for medical use in Japan in 2018,[3] and in the United States in September 2022.[2][4]
Medical uses
[edit]Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.[1][3]
Adverse effects
[edit]The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.[3]
Pharmacology
[edit]Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.[5] Omidenepag is a selective prostaglandin E2 receptor agonist.[6][7]
History
[edit]Omidenepag was developed by Ube Industries and Santen Pharmaceutical.[3]
References
[edit]- ^ a b c "Omlonti- omidenepag isopropyl solution/ drops". DailyMed. 30 September 2022. Retrieved 16 October 2022.
- ^ a b "Drug Approval Package: Omlonti". U.S. Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022.
- ^ a b c d e f Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925–1929. doi:10.1007/s40265-018-1016-1. PMID 30465134. S2CID 53721056.
- ^ "Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension" (Press release). Santen. 26 September 2022. Retrieved 1 October 2022 – via Business Wire.
- ^ "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. Archived from the original on 8 January 2022. Retrieved 8 January 2022.
- ^ Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018). "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science. 59 (1): 145–153. doi:10.1167/iovs.17-22745. PMID 29332128.
- ^ Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020). "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports. 10 (1): 16018. Bibcode:2020NatSR..1016018I. doi:10.1038/s41598-020-72538-x. PMC 7524797. PMID 32994409.
External links
[edit]- "Omidenepag". Drug Information Portal. U.S. National Library of Medicine.
- "Omidenepag isopropyl". Drug Information Portal. U.S. National Library of Medicine.
- "Omidenepag". NCI Thesaurus.
- "Omidenepag isopropyl". NCI Thesaurus.